Experimental Drug Proves Superior to Eculizumab as a Treatment for Paroxysmal Nocturnal Hemoglobinuria
source: pixabay.com

Experimental Drug Proves Superior to Eculizumab as a Treatment for Paroxysmal Nocturnal Hemoglobinuria

According to a story from BioSpace, the biopharmaceutical company Apellis Pharmaceuticals, Inc., has recently announced the results of its phase 3 clinical trial, which was testing the company's investigational drug…

Continue Reading Experimental Drug Proves Superior to Eculizumab as a Treatment for Paroxysmal Nocturnal Hemoglobinuria
ICYMI: A New Year, a New Autoinflammatory Disease, and a Promising New Drug
source: pixabay.com

ICYMI: A New Year, a New Autoinflammatory Disease, and a Promising New Drug

  According to a recent article in Pharma Tutor, researchers at NHGRI, a division of the National Institute of Health, identified the biological cause of a newly-discovered autoinflammatory disease they named…

Continue Reading ICYMI: A New Year, a New Autoinflammatory Disease, and a Promising New Drug
A Biosimilar Drug for Treating Rheumatoid Arthritis and Ankylosing Spondylitis Begins Phase 3 Trials
source: pixabay.com

A Biosimilar Drug for Treating Rheumatoid Arthritis and Ankylosing Spondylitis Begins Phase 3 Trials

According to a story from Acrofan, the biotechnology company Clover Pharmaceuticals Inc. has recently announced that the first patient has been dosed in its phase 3 clinical study. This study…

Continue Reading A Biosimilar Drug for Treating Rheumatoid Arthritis and Ankylosing Spondylitis Begins Phase 3 Trials
A Polycystic Kidney Disease Patient’s Advertisement for a Kidney Donor Finds a Surprising Match
source: pixabay.com

A Polycystic Kidney Disease Patient’s Advertisement for a Kidney Donor Finds a Surprising Match

  By Rachel Whetstone from In The Cloud Copy Shelly Wheaton began a car sign campaign in September to look for a live kidney donor. She was on dialysis because…

Continue Reading A Polycystic Kidney Disease Patient’s Advertisement for a Kidney Donor Finds a Surprising Match

Layers of Paperwork Slow Down Individualized Medications from Reaching Patients, Technology can Speed it Up

As originally reported in Quest Qunam and Sure Scripts; for manydiseases, time is of the essence in terms of treatment. The patient's health will deteriorate irreversibly thout treatment. However, with…

Continue Reading Layers of Paperwork Slow Down Individualized Medications from Reaching Patients, Technology can Speed it Up
IL-23 Inhibitors May be a Leading Treatment for Psoriasis and Psoriatic Arthritis
source: pixabay.com

IL-23 Inhibitors May be a Leading Treatment for Psoriasis and Psoriatic Arthritis

The 2019 European Academy of Dermatology and Venereology Congress was held in Madrid, Spain. During this conference, a symposium was held discussing IL-23 inhibition in psoriasis. Here are some of…

Continue Reading IL-23 Inhibitors May be a Leading Treatment for Psoriasis and Psoriatic Arthritis